微血管减压术治疗椎基底动脉延长扩张症继发三叉神经痛的系统评价与荟萃分析
汇总分析显示初始完全疼痛缓解率为95.8%,末次随访持续缓解率为92.6%,疼痛复发率为5.5%,永久性并发症发生率为2.4%。作者认为MVD对经选择的VBD-TN患者可提供有效持久的疼痛缓解,但鉴于现有证据的回顾性性质,应视为有前景的治疗选择而非确定性标准治疗。
要点
- MVD治疗VBD-TN的汇总初始完全缓解率为95.8%,末次随访持续缓解率为92.6%。
- 疼痛复发率为5.5%,需补救手术者占1.3%,永久性并发症发生率为2.4%。
- 既往毁损性手术与更高并发症率相关,V2受累预示更好的长期疼痛控制。
核心结论
- MVD对经选择的VBD-TN患者可提供有效且持久的疼痛缓解,永久性并发症发生率低,但总体并发症负担具有临床意义。
- 鉴于现有证据均为回顾性研究,MVD应被视为有前景的治疗选择而非确定性标准治疗。
研究设计与样本
- 遵循PRISMA指南的系统评价与荟萃分析,检索PubMed、Embase、Scopus和Web of Science自建库至2025年8月22日。
- 纳入报告VBD-TN患者接受MVD且可提取疼痛结局、复发、补救干预或并发症数据的研究。
主要发现
- 患者平均年龄范围54.0至67.3岁,男性占57.8%(182/315)。
- 汇总初始完全疼痛缓解率为95.8%(95% CI 92.3-98.2),末次随访持续缓解率为92.6%(95% CI 88.4-96.1)。
- 初始充分缓解率为99.9%(95% CI 98.2-100%),末次随访为95.9%(95% CI 91.8-98.8)。
- 疼痛复发率为5.5%(95% CI 2.9-8.9),需补救手术者占1.3%(95% CI 0.2-3.1),永久性并发症发生率为2.4%(95% CI 0.8-4.8)。
- Meta回归提示既往毁损性手术与更高并发症率相关,V2受累预示更好的长期疼痛控制。
关键数值与推荐
- 完全疼痛缓解定义为BNI-I,充分缓解定义为BNI-I至IIIb。
- 汇总初始完全缓解率95.8%(95% CI 92.3-98.2),末次随访持续缓解率92.6%(95% CI 88.4-96.1)。
- 汇总疼痛复发率5.5%(95% CI 2.9-8.9),补救手术率1.3%(95% CI 0.2-3.1),永久性并发症发生率2.4%(95% CI 0.8-4.8)。
临床怎么用
- 对经选择的VBD-TN患者,MVD可考虑为有前景的治疗选项,但需向患者说明总体并发症负担。
- 术前应关注既往毁损性手术史(与更高并发症率相关)及V2受累(预示更好长期疼痛控制)。
局限性
- 现有证据均为回顾性研究,MVD不应被视为确定性标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trigeminal neuralgia (TN) caused by vertebrobasilar dolichoectasia (VBD) is a rare but particularly challenging entity. Microvascular decompression (MVD) is considered the most definitive treatment; however, outcomes in this subgroup remain incompletely characterized. METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines. PubMed, Embase, Scopus, and Web of Science were searched from inception through August 22, 2025. Eligible studies reported on patients with VBD-TN undergoing MVD with extractable data on pain outcomes, recurrence, salvage interventions, or complications. Complete relief was defined as Barrow Neurological Institute (BNI)-I, while adequate relief included BNI-I to IIIb. RESULTS: Thirteen studies involving 315 patients were analyzed. The mean age ranged from 54.0 to 67.3 years, with 57.8% (182/315) being males. The pooled initial complete pain relief rate was 95.8% (95% CI, 92.3-98.2), with sustained relief at the last follow-up in 92.6% (95% CI, 88.4-96.1). Adequate relief was nearly universal, at 99.9% (95% CI, 98.2-100%) initially and 95.9% (95% CI, 91.8-98.8%) at the last follow-up. Pain recurrence occurred in 5.5% (95% CI, 2.9-8.9%), and salvage procedures were required in 1.3% (95% CI, 0.2-3.1%). The permanent morbidity was low at 2.4% (95% CI, 0.8-4.8%). Meta-regression indicated that prior ablative procedures were associated with higher complication rates, whereas V2 involvement predicted better long-term pain control. CONCLUSION: MVD appears to provide effective and durable pain relief for selected patients with VBD-TN, with low permanent morbidity but a clinically meaningful overall complication burden. Given the retrospective nature of the available evidence, MVD should be considered a promising treatment option rather than a definitive standard of care.
引用
- Hajikarimloo B, Mohammadzadeh I, Tos SM, et al. Microvascular decompression for trigeminal neuralgia secondary to vertebrobasilar dolichoectasia: a systematic review and meta-analysis. Acta Neurochir (Wien). 2026. PMID: 42207302. doi:10.1007/s00701-026-06925-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。